Passa al contenuto
Merck
  • Electrotransfection and lipofection show comparable efficiency for in vitro gene delivery of primary human myoblasts.

Electrotransfection and lipofection show comparable efficiency for in vitro gene delivery of primary human myoblasts.

The Journal of membrane biology (2014-12-24)
Tomaz Mars, Marusa Strazisar, Katarina Mis, Nejc Kotnik, Katarina Pegan, Jasna Lojk, Zoran Grubic, Mojca Pavlin
ABSTRACT

Transfection of primary human myoblasts offers the possibility to study mechanisms that are important for muscle regeneration and gene therapy of muscle disease. Cultured human myoblasts were selected here because muscle cells still proliferate at this developmental stage, which might have several advantages in gene therapy. Gene therapy is one of the most sought-after tools in modern medicine. Its progress is, however, limited due to the lack of suitable gene transfer techniques. To obtain better insight into the transfection potential of the presently used techniques, two non-viral transfection methods--lipofection and electroporation--were compared. The parameters that can influence transfection efficiency and cell viability were systematically approached and compared. Cultured myoblasts were transfected with the pEGFP-N1 plasmid either using Lipofectamine 2000 or with electroporation. Various combinations for the preparation of the lipoplexes and the electroporation media, and for the pulsing protocols, were tested and compared. Transfection efficiency and cell viability were inversely proportional for both approaches. The appropriate ratio of Lipofectamine and plasmid DNA provides optimal conditions for lipofection, while for electroporation, RPMI medium and a pulsing protocol using eight pulses of 2 ms at E = 0.8 kV/cm proved to be the optimal combination. The transfection efficiencies for the optimal lipofection and optimal electrotransfection protocols were similar (32 vs. 32.5%, respectively). Both of these methods are effective for transfection of primary human myoblasts; however, electroporation might be advantageous for in vivo application to skeletal muscle.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Fosfato di potassio, ACS reagent, ≥99.0%
Sigma-Aldrich
Fosfato di potassio, ACS reagent, ≥98%
Sigma-Aldrich
Fosfato di potassio, powder, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
L-Glutathione reduced, suitable for cell culture, BioReagent, ≥98.0%, powder
Sigma-Aldrich
Fosfato di potassio, buffer substance, anhydrous, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.5-100.5%
Sigma-Aldrich
Fosfato di potassio, puriss. p.a., ACS reagent, anhydrous, ≥99.0% (T)
Sigma-Aldrich
Fosfato di potassio, meets analytical specification of Ph. Eur., NF, E340, anhydrous, 98-100.5% (calc. to the dried substance)
Sigma-Aldrich
Fosfato di potassio, for molecular biology, ≥98.0%
Sigma-Aldrich
Fosfato di potassio, anhydrous, for luminescence, for molecular biology, BioUltra, ≥99.0% (T)
Sigma-Aldrich
Potassium phosphate dibasic solution, 1.0 M
Sigma-Aldrich
Fosfato di potassio, BioUltra, for molecular biology, anhydrous, ≥99.5% (T)
Sigma-Aldrich
L-Glutathione reduced, ≥98.0%
Sigma-Aldrich
Fosfato di potassio, 99.99% trace metals basis
Sigma-Aldrich
Fosfato di potassio, 99.95% trace metals basis
Sigma-Aldrich
Fosfato di potassio, ReagentPlus®
USP
Fosfato di potassio, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Fosfato di potassio, reagent grade, ≥98.0%
Supelco
Glutathione, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Potassium phosphate dibasic, meets USP testing specifications
Sigma-Aldrich
L-Glutathione reduced, BioXtra, ≥98.0%
Supelco
Fosfato di potassio, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Fosfato di potassio, tested according to Ph. Eur., anhydrous
Glutathione, European Pharmacopoeia (EP) Reference Standard